Deep Genomics Overview
Pro stress-test →Deep Genomics is an AI-powered platform for RNA biology that accelerates genetic therapy discovery. The company focuses on untangling complex RNA data to identify novel targets and therapeutic candidates for genetic conditions, leveraging a proprietary AI platform including its flagship BigRNA model that uses machine learning to analyze vast RNA biology data. This positions Deep Genomics as a pioneer in applying advanced AI to address previously intractable genetic diseases through RNA-based therapeutics.
Strategic Profile
Pro stress-test →The company's AI platform accelerates early-stage drug discovery and the design of RNA-based therapies. Deep Genomics ranks 9th among 788 active AI-drug discovery competitors and stands 4th in total funding within its competitive set. With significant venture backing and a focused platform approach, the company is positioned as a leading pure-play AI drug discovery platform for rare and genetic diseases where RNA therapeutics can address unmet clinical needs.
Competitive Landscape
Pro stress-test →Competitors include OneThree Biotech, Caris Life Sciences, Phenomic AI, Genesis Molecular AI, and Stoke Therapeutics. Other notable players in AI drug discovery include Atomwise (University of Toronto-affiliated) and UK-based Exscientia (also SoftBank-backed); Deep Genomics' differentiator is that its AI can program RNA therapy for almost any gene at any genetic position. Deep Genomics is the most focused on RNA-specific drug discovery and design.
Industry Context
Deep Genomics operates in Clinical AI & Drug Discovery.
Key facts
Founded: 2014 · Headquarters: Toronto, Canada · Employees: 108 (as of April 2026) · Revenue: Not publicly disclosed · Market cap: N/A